Author

C.-J. Liu

NYU Langone HealthORCID 0000-0002-7181-8032Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

C.-J. Liu6 papers · Broad Institute

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

Wenyu FuiD· 2 shared Andrew C. HechtiD· 1 shared Aubryanna HettinghouseiD· 1 shared Chao WangiD· 1 shared Chen ZhangiD· 1 shared Damien M. LaudieriD· 1 shared Elena GrossiiD· 1 shared Guozhi XiaoiD· 1 shared

Activity by Year

2019-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

Wenyu FuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioengineeringOsteoarthritis and CartilagePeer-reviewedMar 24, 2025

TNFR1-mediated senescence and lack of TNFR2-signaling limit human intervertebral disc cell repair in back pain conditions

Jennifer Gansau, Elena Grossi, Levon Rodriguez…·James C. Iatridis

This study identifies TNFR1-mediated senescence and limited TNFR2 signaling as barriers to intervertebral disc cell repair in back pain, suggesting immunomodulation as a therapeutic strategy.

5 citations

𝕏 PostBluesky

Molecular BiologyAnnals of the Rheumatic DiseasesPeer-reviewedOct 15, 2019

Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against autoimmune diseases

Ronghan Liu, Yuehong Chen, Wenyu Fu…·C.-J. Liu

This study identifies Fexofenadine as an inhibitor of TNF signaling through targeting cytosolic phospholipase A2, showing therapeutic potential in autoimmune diseases.

59 citations

mouseexperimental assay

𝕏 PostBluesky